Regeneron Pharmaceuticals Inc. sell Bank of America Co.
Summary
This prediction is currently active. The prediction currently has a disappointing performance of 21.77%. This prediction currently runs until 12.04.25. The prediction end date can be changed by Bank_of_America_Co_ at any time. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | -3.084% | -3.084% |
iShares Core DAX® | -2.385% | 3.986% |
iShares Nasdaq 100 | -4.527% | -0.258% |
iShares Nikkei 225® | -4.129% | 4.382% |
iShares S&P 500 | -2.885% | 1.387% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
29.03.23
29.03.24
30.03.24